Company: PRME
Filing Date: 2025-07-02
Form Type: PRE 14A
Source: 0001193125-25-155000
Chunk: 12

Company: Prime Medicine, Inc.
Filing Date: 2025-07-02
Form: PRE 14A
Chunk 12
---
 were granted from August 4, 2021 through March 1, 2025, and currently have per share exercise prices between $2.52 and $18.22. Each holder of an Eligible Option must continue to be an employee of the Company or a
member of the Board, as applicable, through the Repricing Date in order to participate in the Option Repricing. For the avoidance of doubt, options held by Eligible Optionholders that have a per share exercise price that is below the Repriced
Exercise Price will not be considered Eligible Options and will not be impacted by the Option Repricing in any manner. Except as modified by the Option Repricing, all other terms and conditions of the Eligible Options, including, without limitation,
any provisions with respect to vesting and term of the options, will remain in full force and effect.

On June 22, 2025, the Board
approved, upon the recommendation of the Compensation Committee of the Board (the “Compensation Committee”), subject to the approval of the stockholders at the Special Meeting, the Option Repricing. If approved by the stockholders at the
Special Meeting, effective as of the Repricing Date, the per share exercise price of each Eligible Option held by an Eligible Optionholder who is an employee of the Company or a member of the Board on the Repricing Date, as applicable, will
automatically be reduced to the greater of (i) $2.42 per share of our common stock, which was the exercise price per share of the annual option grants made by the Company to employees in March 2025 and (ii) the closing trading price per
share of our common stock on The Nasdaq Global Market on the effective date of approval by the stockholders of the Company at the Special Meeting (such date, the “Repricing Date,” and such exercise price per share of our common stock, the
“Repriced Exercise Price”) without any action on the part of the Eligible Optionholders; provided, however, that an Eligible Option will revert to its original exercise price per share (the “Original Price”) if (i) such
Eligible Option is exercised prior to the applicable Retention Date (as defined below), which shall be (x) the one-year anniversary of the Repricing Date for Eligible Options held by employees who are not
executive officers of the Company on the Repricing Date or (y) the 18-month anniversary of the Repricing Date for